Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling

• Published in: American journal of physiology. Heart and circulatory physiology Vol. 298; no. 2; pp. H679 - H687
• Main Authors: Merkel, Matthias J, Liu, Lijuan, Cao, Zhiping, Packwood, William, Young, Jennifer, Alkayed, Nabil J, Van Winkle, Donna M
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.02.2010
• Subjects: 8,11,14-Eicosatrienoic Acid - analogs & derivatives; 8,11,14-Eicosatrienoic Acid - metabolism; Animals; Apoptosis; Cell Survival - physiology; Cells; Cells, Cultured; Disease Models, Animal; Epoxide Hydrolases - antagonists & inhibitors; Epoxide Hydrolases - genetics; Epoxide Hydrolases - metabolism; Glucose; Janus Kinases - metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Mutation - genetics; Myocardial Reperfusion Injury - metabolism; Myocardial Reperfusion Injury - pathology; Myocardial Reperfusion Injury - prevention & control; Myocytes, Cardiac - metabolism; Myocytes, Cardiac - pathology; Polymorphism; Polymorphism, Single Nucleotide - genetics; Proteins; Signal Transduction - physiology; STAT3 Transcription Factor - metabolism
• ISSN: 0363-6135; 1522-1539
• DOI: 10.1152/ajpheart.00533.2009

1 Anesthesiology and 2 Research Services, Veterans Affairs Medical Center, Portland; and 3 Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, Oregon Submitted June 11, 2009 ; accepted in final form December 8, 2009 Soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids (EETs), primarily 14,15-EET. EETs are derived from arachidonic acid via P -450 epoxygenases and are cardioprotective. We tested the hypothesis that sEH deficiency and pharmacological inhibition elicit tolerance to ischemia via EET-mediated STAT3 signaling in vitro and in vivo. In addition, the relevance of single nucleotide polymorphisms (SNPs) of EPHX2 (the gene encoding sEH) on tolerance to oxygen and glucose deprivation and reoxygenation and glucose repletion (OGD/RGR) was assessed in male C57BL\6J (WT) or sEH knockout (sEHKO) cardiomyocytes by using transactivator of transcription (TAT)-mediated transduction with sEH mutant proteins. Cell death and hydrolase activity was lower in Arg287Gln EPHX2 mutants vs. nontransduced controls. Excess 14,15-EET and SEH inhibition did not improve cell survival in Arg287Gln mutants. In WT cells, the putative EET receptor antagonist, 14,15-EEZE, abolished the effect of 14,15-EET and sEH inhibition. Cotreatment with 14,15-EET and SEH inhibition did not provide increased protection. In vitro, STAT3 inhibition blocked 14,15-EET cytoprotection, but not the effect of SEH inhibition. However, STAT3 small interfering RNA (siRNA) abolished cytoprotection by 14,15-EET and sEH inhibition, but cells pretreated with JAK2 siRNA remained protected. In vivo, STAT3 inhibition abolished 14,15-EET-mediated infarct size reduction. In summary, the Arg287Gln mutation is associated with improved tolerance against ischemia in vitro, and inhibition of sEH preserves cardiomyocyte viability following OGD/RGR via an EET-dependent mechanism. In vivo and in vitro, 14,15-EET-mediated protection is mediated in part by STAT3. eicosanoid; oxygen and glucose deprivation; reoxygenation and glucose repletion; 14,15-EET; N -adamantanyl- N' -dodecanoic acid urea Address for reprint requests and other correspondence: D. M. Van Winkle, Anesthesiology Service, Veterans Affairs Medical Center, Mail Code: P3ANES, 3710 SW US Veterans Hospital Rd., Portland, OR 97239 (e-mail: donna.vanwinkle{at}med.va.gov ).